c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells

Background Malignant gliomas rank among the most lethal cancers. Gliomas display a striking cellular heterogeneity with a hierarchy of differentiation states. Recent studies support the existence of cancer stem cells in gliomas that are functionally defined by their capacity for extensive self-renewal and formation of secondary tumors that phenocopy the original tumors. As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells. Methodology/Principal Findings Based on previous methods that we and others have employed, tumor cell populations were enriched or depleted for cancer stem cells using the stem cell marker CD133 (Prominin-1). We characterized c-Myc expression in matched tumor cell populations using real time PCR, immunoblotting, immunofluorescence and flow cytometry. Here we report that c-Myc is highly expressed in glioma cancer stem cells relative to non-stem glioma cells. To interrogate the significance of c-Myc expression in glioma cancer stem cells, we targeted its expression using lentivirally transduced short hairpin RNA (shRNA). Knockdown of c-Myc in glioma cancer stem cells reduced proliferation with concomitant cell cycle arrest in the G0/G1 phase and increased apoptosis. Non-stem glioma cells displayed limited dependence on c-Myc expression for survival and proliferation. Further, glioma cancer stem cells with decreased c-Myc levels failed to form neurospheres in vitro or tumors when xenotransplanted into the brains of immunocompromised mice. Conclusions/Significance These findings support a central role of c-Myc in regulating proliferation and survival of glioma cancer stem cells. Targeting core stem cell pathways may offer improved therapeutic approaches for advanced cancers.

[1]  F. Pistollato,et al.  Optimized Flow Cytometric Analysis of Central Nervous System Tissue Reveals Novel Functional Relationships Among Cells Expressing CD133, CD15, and CD24 , 2007, Stem cells.

[2]  C. Arvanitis,et al.  Conditional transgenic models define how MYC initiates and maintains tumorigenesis. , 2006, Seminars in cancer biology.

[3]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[4]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[5]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[6]  Robert B Boxer,et al.  Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. , 2004, Cancer cell.

[7]  J. Dick,et al.  Targeting of CD44 eradicates human acute myeloid leukemic stem cells , 2006, Nature Medicine.

[8]  O. Perez,et al.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. , 2008, Cancer research.

[9]  E. Markakis,et al.  c-myc oncogene family expression in glioblastoma and survival. , 1999, Surgical neurology.

[10]  D. Felsher,et al.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. , 2003, Blood.

[11]  W. El-Deiry,et al.  Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  C. Heeschen,et al.  Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. , 2007, Cell stem cell.

[13]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[14]  D. Zhuang,et al.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle , 2008, Oncogene.

[15]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells From Adult Human Fibroblasts by Defined Factors , 2008 .

[16]  Malin Parmar,et al.  Strengths and limitations of the neurosphere culture system , 2006, Molecular Neurobiology.

[17]  Takashi Aoi,et al.  Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.

[18]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[19]  E. Thompson,et al.  The many roles of c-Myc in apoptosis. , 1998, Annual review of physiology.

[20]  Andreas Trumpp,et al.  More than just proliferation: Myc function in stem cells. , 2005, Trends in cell biology.

[21]  Eran Segal,et al.  Module map of stem cell genes guides creation of epithelial cancer stem cells. , 2008, Cell stem cell.

[22]  G. Prendergast,et al.  Mechanisms of apoptosis by c-Myc , 1999, Oncogene.

[23]  Mark J. Murphy,et al.  c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. , 2004, Genes & development.

[24]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[25]  Lene Rask,et al.  Astroglial c-Myc Overexpression Predisposes Mice to Primary Malignant Gliomas* , 2003, The Journal of Biological Chemistry.

[26]  G. Evan,et al.  Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia , 2004, Oncogene.

[27]  L. Zon,et al.  Effects of RAS on the genesis of embryonal rhabdomyosarcoma. , 2007, Genes & development.

[28]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[30]  D. Roop,et al.  Deregulated expression of c-Myc depletes epidermal stem cells , 2001, Nature Genetics.

[31]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[32]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[33]  J. Dick,et al.  A human colon cancer cell capable of initiating tumour growth in immunodeficient mice , 2007, Nature.

[34]  Kathryn A. O’Donnell,et al.  The c-Myc target gene network. , 2006, Seminars in cancer biology.

[35]  R. McLendon,et al.  Targeting cancer stem cells through L1CAM suppresses glioma growth. , 2008, Cancer research.

[36]  P. Dalerba,et al.  Identification of pancreatic cancer stem cells. , 2006, Cancer research.

[37]  L. Ricci-Vitiani,et al.  Identification and expansion of human colon-cancer-initiating cells , 2007, Nature.

[38]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[39]  P. Knoepfler.  Why myc? An unexpected ingredient in the stem cell cocktail. , 2008, Cell stem cell.

[40]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[41]  A. Gartel,et al.  Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[43]  M. Huang,et al.  A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. , 2006, Experimental hematology.

[44]  I. Weissman,et al.  Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma , 2007, Proceedings of the National Academy of Sciences.

[45]  Qiulian Wu,et al.  Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.

[46]  M. Henriksson,et al.  The Myc oncoprotein as a therapeutic target for human cancer. , 2006, Seminars in cancer biology.

[47]  Hongye Liu,et al.  Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma , 2007, Neuron.

[48]  R. Arceci.  PML targeting eradicates quiescent leukaemia-initiating cells , 2009 .

[49]  J. Kaptein,et al.  Anti-IgM-mediated Regulation of c-myc and Its Possible Relationship to Apoptosis* , 1996, The Journal of Biological Chemistry.

[50]  Zhiping Weng,et al.  Global mapping of c-Myc binding sites and target gene networks in human B cells , 2006, Proceedings of the National Academy of Sciences.

[51]  M. Caligiuri,et al.  A cell initiating human acute myeloid leukaemia after transplantation into SCID mice , 1994, Nature.

[52]  M. Todaro,et al.  Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. , 2007, Cell stem cell.

[53]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[54]  L. M. Facchini,et al.  Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. , 1994, Oncogene.

[55]  T. Schlange,et al.  Novel c‐MYC target genes mediate differential effects on cell proliferation and migration , 2007, EMBO reports.

[56]  D. Brash,et al.  Role of E2F1 in Apoptosis: A case Study in Feedback Loops , 2004, Cell cycle.

[57]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[58]  Daniel Medina,et al.  Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. , 2008, Cancer research.

[59]  M. Eilers,et al.  Control of cell proliferation by Myc. , 1998, Trends in cell biology.

[60]  K. Black,et al.  Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.

[61]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[62]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[63]  David N Louis,et al.  Molecular pathology of malignant gliomas. , 2006, Annual review of pathology.

[64]  F M Watt,et al.  c-Myc promotes differentiation of human epidermal stem cells. , 1997, Genes & development.